An Open-label Multicenter Study on the Efficacy of Continuous Oral Dosing of Vemurafenib on Tumour Response in Previously Treated Patients With Metastatic Melanoma

Trial Profile

An Open-label Multicenter Study on the Efficacy of Continuous Oral Dosing of Vemurafenib on Tumour Response in Previously Treated Patients With Metastatic Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms BRIM-2
  • Sponsors Roche
  • Most Recent Events

    • 26 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 11 Oct 2016 Results of an exploratory analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM studies presented at the 41st European Society for Medical Oncology Congress
    • 11 Oct 2016 Results (n=809) of a pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM study identifying prognostic subgroups and impact of treatment for post-progression overall survival, presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top